Sr. Director, Forecasting & Strategic Analytics

About Spring Works Therapeutics

Spring Works Therapeutics, a healthcare company of Merck KGaA, Darmstadt, Germany, is a commercial‑stage biopharmaceutical company dedicated to improving the lives of patients with rare tumors. We have developed and are commercializing the first and only FDA and EC approved medicines for adults with desmoid tumors and for adults and children with neurofibromatosis type 1‑associated plexiform neurofibromas (NF1‑PN). At Spring Works, we are committed to finding answers people with rare tumors need.

We thrive in an atmosphere of passion and tenacity, fueled by the excitement of the possibilities science may unlock and driven to work with urgency because of the importance of our work. We value authenticity because diverse backgrounds, cultures, styles and abilities can only help us find the answers that people with rare tumors are looking for.

The Senior Director, Forecasting and Strategic Analytics is a hands‑on leader responsible for building out the forecasting capability for the U.S. Rare Tumor business and leading forecasting operations, which includes the end‑to‑end revenue and volume demand forecasting, reporting, and analytics processes. This role is responsible for building a robust, scalable forecasting process aligned to the F0‑F3 forecasting cycles as well as any ad‑hoc forecast analyses/initiatives to inform commercial decisions.

This role works closely with the Brand Integrated Insights Lead and the Brand Marketing team to develop and execute the forecasting strategy for each brand in the Rare Tumor portfolio. The Senior Director, Forecasting, is accountable for the deliverables of each forecast cycle and works in a highly cross‑functional team to ensure the successful development and delivery of operational and strategic forecasts, and other analytics projects.

The Senior Director, Forecasting, has one direct report.

This role will be required to work onsite 2 days a week (Tuesday and Wednesday), or more depending on business needs.

• Establish and oversee the commercial forecasting process within the Rare Tumor business. Create, update, and maintain forecast models based on appropriate primary and secondary data and market understanding and transition external vendor forecast models and support to fully internal Spring Works‑supported forecasting capability.
• Manage U.S. forecasts for Desmoid Tumor, NF1‑PN, and Tenosynovial Giant Cell Tumor therapeutic areas. Provide transparency into key drivers, sensitivities, risks & opportunities to ensure the Organization remains agile and data‑driven in its decision‑making.
• Drive the development, maintenance, harmonization, and continuous improvement of the various forecasting models used to produce commercial revenue projections for all forecast cycles, S&OP processes, and all associated analytics and supporting presentation materials for review with all levels of brand and Spring Works leadership.
• Understand brand and market dynamics to facilitate optimal decision‑making through cross‑functional collaboration with Sales, Marketing, Market Access, Finance, and Production Planning.
• Identify and use a comprehensive set of data/information—analogs, Rx/claims data, medical data (epidemiology, medical publications, etc.)—to build the most robust forecast assumptions; work collaboratively across Commercial and Medical function to gain alignment on assumptions.
• Develop scenarios to assess the impact of different market events and team executions; define opportunities and risks associated with the forecast and provide proactive analysis of drivers to determine key inflection points for the business forecast and refine forecasts on an ongoing basis leveraging most recent data and market events; provide guidance on future performance.
• Partner with Finance and Supply Chain and other Operations Partners to inform Long‑Range Planning and the Sales & Operations Planning process and track key performance indicators (KPIs) impacting the commercial forecast. Explain deviations in performance from forecast and suggest strategic levers to address these…